03/31/2026
PROMISING!
The U.S. Food and Drug Administration has granted fast track designation to ZW191, a novel folate receptor α (FRα) targeting antibody drug conjugate (ADC), for the treatment of patients with advanced or metastatic platinum-resistant ovarian cancer.
ZW191 is currently under evaluation in a phase 1 trial that has already demonstrated activity among patients with platinum-resistant ovarian cancer. Let's keep hoping!
Read and SHARE: https://www.cancernetwork.com/view/fda-grants-fast-track-designation-to-fr-adc-in-advanced-proc